Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding

Am Heart J. 2015 Jan;169(1):1-3. doi: 10.1016/j.ahj.2014.09.007. Epub 2014 Sep 28.

Authors

John A Cairns¹, Jeffrey I Weitz²

Affiliations

¹ Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: john.cairns@ubc.ca.
² Department of Medicine, McMaster University, and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.

PMID: 25497240
DOI: 10.1016/j.ahj.2014.09.007

No abstract available

Publication types

Editorial

MeSH terms

Antithrombins / administration & dosage
Antithrombins / therapeutic use
Atrial Fibrillation / complications
Benzimidazoles / administration & dosage
Benzimidazoles / therapeutic use
Dabigatran
Factor Xa Inhibitors / therapeutic use*
Hemorrhage / etiology
Humans
International Normalized Ratio
Morpholines / administration & dosage
Morpholines / therapeutic use
Pyrazoles / therapeutic use*
Pyridones / therapeutic use*
Rivaroxaban
Stroke / etiology
Stroke / prevention & control*
Thiophenes / administration & dosage
Thiophenes / therapeutic use
Vitamin K / antagonists & inhibitors
Warfarin / administration & dosage
Warfarin / therapeutic use*
beta-Alanine / administration & dosage
beta-Alanine / analogs & derivatives
beta-Alanine / therapeutic use

Substances

Antithrombins
Benzimidazoles
Factor Xa Inhibitors
Morpholines
Pyrazoles
Pyridones
Thiophenes
beta-Alanine
Vitamin K
apixaban
Warfarin
Rivaroxaban
Dabigatran